Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pfizer Ltd. Regulatory Filings 2025

Feb 4, 2025

60507_rns_2025-02-04_5bfb3646-bce8-48df-8e08-e28430291317.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

==> picture [100 x 41] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

February 4, 2025

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform you that, the Company has received an Order on February 3, 2025 (“Order”), from the Office of the Assistant Commissioner, Central Goods and Service Tax (“GST”) Division-Badli, New Delhi, 110002, basis the GST Audit conducted by the Department, for the period July 2017 to March 2021 for Delhi GSTIN, for a tax demand of Rs. 14,39,072/-, Interest of Rs. 45,462/- and a Penalty of Rs. 14,64,072/- aggregating to a total demand of Rs. 29,48,606/-.

Based on our assessment, we believe that the said demand is not maintainable and the Company is in the process of preferring an appeal against the said Order. The Order has no material impact on the financials, operations or other activities of the Company.

Additional details required to be disclosed pursuant to the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as Annexure A.

Request you to please take the above on record.

Thanking you,

Yours truly, For Pfizer Limited

Digitally signed by PRAJEET NAIR PRAJEET NAIR Date: 2025.02.04 11:30:57 +05'30'

Prajeet Nair

Director – Corporate Services & Company Secretary

Encl.: A/a

CIN: L24231MH1950PLC008311 Email ID: [email protected] Website: www.pfizerltd.co.in

Annexure A

Additional information pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr.No. Particulars Details
1. Name of Authority Office of the Assistant Commissioner, CGSTDivision-Badli,New Delhi 110002
2. Nature and details of the action(s) taken,initiated or order(s) passed. Order Ref No. 06/Supdt/R-32/2025 datedFebruary 2, 2025 passed under Section 74 ofDelhi GST Act, 2017 for the Tax ofRs. 14,39,072/-, Interest of Rs. 45,462/- andPenalty of Rs. 14,64,072 aggregating to a totaldemand of Rs. 29,48,606/-.
3. Date of receipt of direction or order,including any ad-interim or interim orders,or any other communication from theauthority. February 3, 2025
4. Detailsoftheviolation(s)/contravention(s) committed or alleged tobe committed. The Authority has alleged that the Companyhas short paid the taxes and availed excessInput Tax Credit.
5. Impact on financial, operation or otheractivities of the listed entity, quantifiablein monetary terms to the extent possible There is no material impact on financials,operations or other activities of the Company.The Company believes that the said demand isnot maintainable and is in the process ofpreferring to file an appeal against the saidorder/demand.